MUSC research to use he immune system to fight cancer shows it can be done safer, cheaper and better. An SC company pushing ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Abstract Title: Rationale and Study Design for a Phase 2/3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

With a new law that makes it easier for people to access experimental treatments, Montana could become the hub for the ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

Novocure NVCR recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Otsuka's investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the ...

Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.